Trial Profile
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Daratumumab; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DCDP
- 03 Aug 2023 Status changed from active, no longer recruiting to completed.
- 14 Feb 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Jun 2022.
- 22 Jan 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.